thromboxane-A synthase

(redirected from Thromboxane synthase)

thromboxane-A synthase

an enzyme that catalyzes the conversion in platelets of prostaglandin G2 to thromboxane A2. A deficiency of the enzyme causes a defect in the release of platelets. See also thromboxane A2.
References in periodicals archive ?
I also briefly summarize the biochemical and pathophysiological properties of the two other PGE synthases (PGESs) and thromboxane synthase (TXS), which is closely related to PGIS.
2]), which is produced by the action of thromboxane synthase on the prostaglandine endoperoxide [H.
The VCU team reported that thromboxane synthase - an important inflammatory enzyme - is increased in the blood vessels of expectant mothers with preeclampsia.
One enzyme, thromboxane synthase, is responsible for cancer cells spreading quickly through the body.
In addition to the development of EV-077 for complications of diabetes, Evolva has been investigating a novel anti-viral property of this dual thromboxane receptor antagonist and thromboxane synthase inhibitor.
It's irreversible and goes primarily down one of those pathways; it blocks thromboxane synthesis in platelets by inhibiting thromboxane synthase, which is an enzyme in the platelet itself, so we think our mechanism of action is broader.
The trials involved endothelin-receptor antagonists, thromboxane synthase inhibitors, prostanoids, and phosphodiesterase type-5 inhibitors.
Inhibition of Thromboxane Synthase Leads to Cell Cycle Arrest and Apoptosis in Lung Cancer Cells
We incubated additional aliquots with 1 /,mol/L terbogrel (Thomae), an equipotent inhibitor of thromboxane synthase and thromboxane receptors.
The reduction in thromboxane A2 synthase activity was confirmed in a separate study in which thromboxane synthase receptor inhibition was evident after exposure to 1-TDC.
In addition to the development of EV-077 for cardio-renal indications, Evolva has been investigating a novel anti-viral property of this dual thromboxane receptor antagonist and thromboxane synthase inhibitor.
Deficiencies of the enzymes cyclooxygenase and thromboxane synthase are well-documented, and dysfunction or deficiency of thromboxane receptors is known.